Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05882734 · ClinicalTrials.gov registry record · Phase 1
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
A Phase 1 study of Non-Small Cell Lung Cancer, sponsored by EMD Serono Research & Development Institute.
- Active
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
- 20
- Study locations
NCT05882734 is a Phase 1 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by EMD Serono Research & Development Institute. The registered enrollment target is 61 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT05882734, a Phase 1 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by EMD Serono Research & Development Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an Open-label, multicenter clinical study conducted in two Phases to establish the efficacy, safety, tolerability, and pharmacokinetics of the ataxia telangiectasia mutated and Rad3-related protein kinase (ATR) inhibitor Tuvusertib in Combination with Cemiplimab in Participants with Non-Squamous Non-Small Cell Lung Cancer (nsqNSCLC) that has Progressed on Prior Anti-PD-(L)1 and Platinum-based Therapies..
Conditions Studied
Interventions
- DRUG Cemiplimab
- DRUG M1774
Study Locations (20)
Other
- Institut Jules Bordet - Department of Institut Jules Bordet' - Anderlecht
- UZA - Oncology - Edegem
- Jessa Ziekenhuis Hospital - Hasselt
- Universitair Ziekenhuis Brussel - UZB - Jette
- UZ Leuven - Leuven
- CHU de Liège - PARENT - Liège
- CHU Angers - Hôpital Larrey - Service de Pneumologie - Angers
- Centre Hospitalier Intercommunal de Créteil - Service de Pneumologie - Créteil
- CHU Limoges - Hôpital Dupuytren - Unite d'Oncologie Thoracique et Cutanée - Limoges
- Hôpital de la Timone - CPCEM CIC - Bat F 1er étage - Marseille
- Hopital Arnaud de Villeneuve - Service de Pneumologie-Addictologie - Montpellier
- Groupe Hospitalier Sud - Hôpital Haut-Lévêque - Unité d'Explorations Fonctionnelles Respiratoires - Pessac
- ICO - Site René Gauducheau - Service d'Oncologie medicale - Saint-Herblain
- Universitaetsklinikum Giessen und Marburg GmbH - Medizinische Klinik und Poliklinik III - Giessen
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- Millennium Research & Clinical Development - Houston
California
- UCLA Hematology and Oncology - Santa Monica - Santa Monica
Pennsylvania
- UPMC Cancer Center - Pittsburgh
Tennessee
- Tennessee Cancer Specialists - Biomedical Research - Knoxville
Virginia
- Virginia Cancer Specialists, PC - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2023-09-13 |
| Est. Completion | 2026-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05882734
The ClinicalTrials.gov registry entry for NCT05882734 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (91% lower). The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cemiplimab is the first listed.
NCT05882734 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, Texas, California.
Frequently Asked Questions
What is clinical trial NCT05882734 about?
NCT05882734 is a clinical study titled "Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)". This is an Open-label, multicenter clinical study conducted in two Phases to establish the efficacy, safety, tolerability, and pharmacokinetics of the ataxia telangiectasia mutated and Rad3-related protein kinase (ATR) inhibitor Tuvusertib in Combination with Cemiplimab in Participants with Non-Squa...
What is the current status of trial NCT05882734?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2023-09-13. Estimated completion is 2026-03-30.
What conditions does trial NCT05882734 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT05882734?
The interventions under investigation include: Cemiplimab (DRUG), M1774 (DRUG).
Who is sponsoring clinical trial NCT05882734?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05882734 being conducted?
This trial has 20 study locations across California, Pennsylvania, Tennessee, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.